Paolo Pozzilli
Overview
Explore the profile of Paolo Pozzilli including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
248
Citations
4929
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Ibrahim M, Ba-Essa E, Baker J, Cahn A, Ceriello A, Cosentino F, et al.
Diabetes Metab Res Rev
. 2023 Dec;
40(3):e3755.
PMID: 38115715
In the primary care setting providers have more tools available than ever before to impact positively obesity, diabetes, and their complications, such as renal and cardiac diseases. It is important...
12.
Ricottini E, Gatto L, Nusca A, Melfi R, Mangiacapra F, Albano M, et al.
Clin Nutr ESPEN
. 2023 Dec;
58:104-110.
PMID: 38056992
Background And Aims: Leptin is a hormone involved in the regulation of food intake. Previous studies suggested an interplay between leptin, platelet aggregation, and cardiovascular outcome but this issue was...
13.
Maddaloni E, Carlone A, Pitocco D, Leanza G, Suraci C, Altomare M, et al.
Diabetes Obes Metab
. 2023 Nov;
25(11):3415-3419.
PMID: 38014612
No abstract available.
14.
Nazari P, Pozzilli P
Diabetes Res Clin Pract
. 2023 Sep;
204:110896.
PMID: 37683768
Type 2 diabetes (T2DM) and COVID-19 represent a considerable burden of disease for patients and healthcare systems. New evidence is transpiring detailing the existence of a bidirectional relationship between T2DM...
15.
Sordi V, Monti P, Lampasona V, Melzi R, Pellegrini S, Keymeulen B, et al.
Front Endocrinol (Lausanne)
. 2023 Jul;
14:1175640.
PMID: 37409229
Aim: In a recent randomized, multicenter trial (NCT02814838) a short-term anti-inflammatory treatment with ladarixin (LDX; an inhibitor of the CXCR1/2 chemokine receptors) did not show benefit on preserving residual beta...
16.
DSouza F, Buzzetti R, Pozzilli P
Diabetes Metab Res Rev
. 2023 May;
39(5):e3666.
PMID: 37209039
Recent evidence suggests a role for Diabetes Mellitus in adverse outcomes from COVID-19 infection; yet the underlying mechanisms are not clear. Moreover, attention has turned to prophylactic vaccination to protect...
17.
Alhamar G, Briganti S, Maggi D, Viola V, Faraj M, Zannella C, et al.
J Clin Endocrinol Metab
. 2023 Jan;
108(7):e474-e479.
PMID: 36611249
Context: Poor glucose control has been associated with increased mortality in COVID-19 patients with type 1 diabetes (T1D). Objective: This work aimed to assess the effect of prevaccination glucose control...
18.
Strollo R, Vinci C, Man Y, Bruzzaniti S, Piemonte E, Alhamar G, et al.
Diabetologia
. 2022 Oct;
66(1):132-146.
PMID: 36207582
Aims/hypothesis: Antibodies specific to oxidative post-translational modifications (oxPTM) of insulin (oxPTM-INS) are present in most individuals with type 1 diabetes, even before the clinical onset. However, the antigenic determinants of...
19.
Defeudis G, Maddaloni E, Rossini G, Di Tommaso A, Mazzilli R, Di Palma P, et al.
J Clin Med
. 2022 Sep;
11(18).
PMID: 36142982
Background: This is a proof of concept, as a pilot study, with the aim to evaluate continuous glucose monitoring metrics (CGM) in subjects with type 2 diabetes (T2DM), treated with...
20.
Chandrashekhar Joshi S, Pozzilli P
Diabetes Res Clin Pract
. 2022 Aug;
191:110034.
PMID: 35940303
Introduction: The COVID-19 pandemic disproportionately affected patients who had comorbid diabetes mellitus. COVID-19 patients with diabetes experience significantly higher rates of complications and mortality. COVID-induced diabetes is a novel phenomenon...